These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Bone-marrow microinvolvement in non-small cell lung cancer is not a reliable indicator of tumour recurrence and prognosis. Hsu CP SL; Chen CY; Kwang PC; Miao J; Hsia JY; Shai SE Eur J Surg Oncol; 2000 Nov; 26(7):691-5. PubMed ID: 11078616 [TBL] [Abstract][Full Text] [Related]
4. Expression and clinical significance of matrix metalloproteinase (MMP)-26 protein in non-small cell lung cancer. Li L; Mei TH; Zhou XD; Zhang XG Ai Zheng; 2009 Jan; 28(1):60-3. PubMed ID: 19448419 [TBL] [Abstract][Full Text] [Related]
5. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326 [TBL] [Abstract][Full Text] [Related]
6. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival. Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127 [TBL] [Abstract][Full Text] [Related]
7. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer. Byun JH; Lee MA; Roh SY; Shim BY; Hong SH; Ko YH; Ko SJ; Woo IS; Kang JH; Hong YS; Lee KS; Lee AW; Park GS; Lee KY Jpn J Clin Oncol; 2006 May; 36(5):263-8. PubMed ID: 16735371 [TBL] [Abstract][Full Text] [Related]
8. [Prognostic impact of matrix metalloproteinases 2,9, and 11 in stromal cells stage I non-small cell lung cancer]. Drác P; Klein J; Tichý T; Kolek V; Skarda J Cas Lek Cesk; 2007; 146(1):45-7. PubMed ID: 17310584 [TBL] [Abstract][Full Text] [Related]
9. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Herbst RS; Yano S; Kuniyasu H; Khuri FR; Bucana CD; Guo F; Liu D; Kemp B; Lee JJ; Hong WK; Fidler IJ Clin Cancer Res; 2000 Mar; 6(3):790-7. PubMed ID: 10741698 [TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Cox G; Jones JL; O'Byrne KJ Clin Cancer Res; 2000 Jun; 6(6):2349-55. PubMed ID: 10873086 [TBL] [Abstract][Full Text] [Related]
11. Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. Lin TS; Chiou SH; Wang LS; Huang HH; Chiang SF; Shih AY; Chen YL; Chen CY; Hsu CP; Hsu NY; Chou MC; Kuo SJ; Chow KC Oncol Rep; 2004 Oct; 12(4):717-23. PubMed ID: 15375490 [TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. Hofmann HS; Hansen G; Richter G; Taege C; Simm A; Silber RE; Burdach S Clin Cancer Res; 2005 Feb; 11(3):1086-92. PubMed ID: 15709175 [TBL] [Abstract][Full Text] [Related]
13. [Study of prognostic factors in patients with stage I non-small cell lung cancer]. Jiang ZQ; Jiang GL; Shi DR; Zhang RX; Fu XL; Qian H Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):364-8. PubMed ID: 15312349 [TBL] [Abstract][Full Text] [Related]
14. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. Aljada IS; Ramnath N; Donohue K; Harvey S; Brooks JJ; Wiseman SM; Khoury T; Loewen G; Slocum HK; Anderson TM; Bepler G; Tan D J Clin Oncol; 2004 Aug; 22(16):3218-29. PubMed ID: 15249585 [TBL] [Abstract][Full Text] [Related]
16. Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung. Takemoto N; Tada M; Hida Y; Asano T; Cheng S; Kuramae T; Hamada J; Miyamoto M; Kondo S; Moriuchi T Lung Cancer; 2007 Dec; 58(3):376-83. PubMed ID: 17714826 [TBL] [Abstract][Full Text] [Related]
17. Immunocytochemical detection of occult tumor cells in the bone marrow: prognostic impact on early stages of lung cancer. Nosotti M; Tosi D; Palleschi A; Rosso L; Mendogni P; Santambrogio L Eur Surg Res; 2008; 41(3):267-71. PubMed ID: 18594145 [TBL] [Abstract][Full Text] [Related]
18. hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Wang L; Soria JC; Kemp BL; Liu DD; Mao L; Khuri FR Clin Cancer Res; 2002 Sep; 8(9):2883-9. PubMed ID: 12231532 [TBL] [Abstract][Full Text] [Related]
19. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis. Leinonen T; Pirinen R; Böhm J; Johansson R; Ropponen K; Kosma VM Lung Cancer; 2006 Mar; 51(3):313-21. PubMed ID: 16423426 [TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]